Clene’s (CLNN) cash and cash equivalents totaled $9.8 million as of March 31, 2025, compared to $12.2 million as of December 31, 2024. Clene expects that its resources as of March 31, 2025, will be sufficient to fund its operations into the third quarter of 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLNN:
- Optimistic Outlook on Clene’s CNM-Au8 for ALS: Investment Potential Amid Clinical Challenges
- Clene initiated with a Buy at JonesResearch
- Promising Potential of Clene’s CNM-Au8 in MS: Analyst Recommends Buy Rating
- Clene Showcases CNM-Au8® Advancements at Neurology Session
- Clene announces evidence of remyelination, neuronal repair with CNM-Au8